Novel Oral Anti-inflammatory Selected from Rich Drug Portfolio Targeting Chemokine System

ChemoCentryx Awarded $14 Million NIH Grant to Develop Chemokine-Based Immunomodulators October 13, 2003; San Carlos, Calif. — ChemoCentryx, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded the company

ChemoCentryx Establishes World-Class Clinical Advisory Board for IBD

ChemoCentryx and Forest Laboratories to Collaborate on The Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics March 15, 2004; San Carlos, CA and New York, NY — ChemoCentryx, Inc., a privately held focused pharmaceutical company, and Forest

ChemoCentryx Raises $33 Million in Private Financing June 17, 2004; San Carlos, Calif. — ChemoCentryx, Inc. today announced that it has closed a private financing round raising gross proceeds of $33 million. HBM BioVentures and Alta Partners acted as significant new investors in the round.

Results from Phase I Clinical Studies Confirm Once-daily Dosing Regimen

Traficet-EN™ Is Well-Tolerated and Appropriate for Once-Daily Oral Dosing

Investigational New Drug Application on File — Studies to Commence by Year End

Susan M. Kanaya Appointed Chief Financial Officer

ChemoCentryx Names Regina E. Herzlinger to the Company's Board of Directors Mountain View, CA; February 7, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system,